IP Watchdog

JANUARY 9, 2024

Patent and Trademark Office (USPTO) published guidelines for examiners today on the topic of enablement in light of the Supreme Court’s May 2023 decision in Amgen v.

Publishing 114

Publishing Trademark Patent Patent Prosecution 114

Patently-O

NOVEMBER 6, 2022

On Friday, the Supreme Court granted certiorari on two petitions raising intellectual property issues, including the closely-watched enablement case Amgen v. Over the past few years, the Federal Circuit has issued a series of enablement decisions, including Amgen v. The claim in Amgen illustrates this point. 8,829,165: 1.

Invention 63

Invention Art Patent Law Intellectual Property 63

The IPKat

OCTOBER 9, 2023

This 3-day conference promises to offer 200+ private practice and in-house participants a forum of practical discussions surrounding the leading patent litigation topics in Europe, with a compare-and-contrast method with jurisdictions further afield. A UPC Litigation Forum will take place on 22 January too.

Litigation 62

Litigation Patent Editing IP 62

LexBlog IP

JUNE 30, 2023

At present, only one other adalimumab biosimilar, Amgen’s AMJEVITA® (adalimumab-atto), is currently available on the US market, having launched in January 2023, though it is not currently designated as interchangeable. Stay tuned to Big Molecule Watch for continued updates on this topic.

Designs 52

Designs Design Branding Brands 52

Patently-O

OCTOBER 4, 2023

IP Timely Topics CLE – November 14, 2023 – Washington State Bar Association I’m delighted to be presenting again this year at the Washington State Bar Association’s IP section meeting. My presentation will focus on the implications of the Amgen vs. Sanofi decision for both biotech and “regular” tech.

Intellectual Property Law 49

Intellectual Property Law Intellectual Property IP Trademark Law 49

Patently-O

SEPTEMBER 26, 2022

Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) Note also that there are similarities with the pending enablement petition in Amgen v. Full Scope Enablement in Amgen Inc. 4th 1013 (Fed.

Patent Law 125

Patent Law Law Patent Invention 125

LexBlog IP

AUGUST 28, 2023

On appeal, the Federal Circuit affirmed, citing the Supreme Court’s precedent regarding enablement in the recent Amgen Inc. at *5 (citing Amgen , 143 S. This topic was recently previewed in Realtime Data v. then any function that [the inventor] claims for that apparatus is also fully enabled.” ” Id. ” Id.

Invention 52

Invention Patent Application Art Patent 52